Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mecbotamab vedotin
- Development stage
- Phase 2
- Lead developer
- BioAtla
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Mecbotamab vedotin is a conditionally active antibody-drug conjugate (ADC) targeting AXL. It consists of a humanized IgG1 monoclonal antibody that binds to AXL under acidic tumor microenvironment conditions and is conjugated via a cleavable linker to the cytotoxic payload monomethyl auristatin E (MMAE). The drug is designed to selectively bind and kill AXL-expressing cancer cells by delivering MMAE directly into the tumor cell after internalization. Its mechanism includes inhibition of tubulin polymerization leading to mitotic arrest and apoptosis. Mecbotamab vedotin is being developed primarily for solid tumors such as non-small cell lung cancer (NSCLC), soft tissue sarcoma (with orphan drug designation), ovarian cancer, and other advanced solid tumors[1][2][4][5][6].
- Brand names
- mecbotamab vedotin
- Other names
- CAB-Axl-ADCBA3011BA-3011BA 3011HTBA-3011HTBA3011HTBA 3011
02
Targets
AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on mecbotamab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mecbotamab vedotin.